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INTRODUCTION AND OBJECTIVES: Precise localization of tumor locus is critically important for successful focal therapy in prostate cancer. The accuracy of multiparametric MRI (mpMRI) for prostate cancer localization is still unknown.
METHODS: We retrospectively analyzed 176 prostate cancer patients who underwent preoperative 3.0T multiparametric MRI (mpMRI) followed by radical prostatectomy (RP) without neoadjuvant androgen deprivation. Images of mpMRI was evaluated by a single radiologist based on PI-RADS version 2. PI-RADS score 4 or greater was considered positive. Tumor distribution was evaluated on radical prostatectomy specimen sliced at 5-mm thick and tumor volume was estimated based on planimetry.
RESULTS: Of the 176 study patients, 79 (45%) had negative mpMRI. Patients with negative mpMRI had smaller index tumor compared with those with positive mpMRI with a marginal significance (1.79 AE 0.25 vs 20.5 AE 0.22 cc., p ¼ 0.05, Figure and Table) . They were also more likely to have clinically insignificant cancer (Gleason score 6 and tumor volume <0.5 cc.) compared with those with positive mpMRI (Tables). However, the sensitivity and specificity for clinically significant prostate cancer was only 60% and 57%, respectively, indicating that mpMRI missed 40% of clinically significant cancer.
CONCLUSIONS: Although negative mpMRI is associated with favorable pathological findings in prostate cancer patients who underwent radical prostatectomy, mpMRI could not safely exclude clinically significant index tumor. Further improvement in the accuracy for tumor localization is warranted for the possible application of mpMRI to plan focal therapy.
Source of Funding: None

MP20-09 EVALUATING MRI FUSION BIOPSY VS SYSTEMATIC ULTRASOUND GUIDED BIOPSY IN PREDICTING HIGH GRADE CANCER AT TIME OF RADICAL PROSTATECTOMY
Hao Nguyen*, Katsuto Shinohara, Janet Cowan, Antonio Westphalen, Matthew Cooperberg, Jeff Simko, Peter Carroll, San Francisco, CA INTRODUCTION AND OBJECTIVES: There is much enthusiasm for multi-parametric MRI (mpMRI)-ultrasound fusion biopsy in those with an elevated PSA, a prior negative biopsy or those on active surveillance. However, the predictive value of MRI e targeted biopsy in predicting final cancer grade has not been well addressed. The uncertainties of both over staging and under staging using MRI fusion targeted biopsy have not been well addressed. We aimed to evaluate the accuracy of cancer risk estimation with MRI fusion biopsy; traditional sextant and anterior (14 cores) ultrasound guided biopsy or the combination, using whole-mount histopathology at time of prostatectomy.
METHODS: We retrospectively analyzed 114 patients who had radical prostatectomy in 2014-2016. All patients had undergone systematic ultrasound guided biopsy and mpMRI fusion biopsy. We compared Gleason Score (GS !7) upgrading or downgrading between MRI fusion and systematic ultrasound guided biopsy to that of the final Gleason score evaluated by whole-mount histopathological analysis. Logistic regression was used to evaluate association to adverse pathological outcome for each biopsy approach.
RESULTS: Of 114 patients, GS !7 cancer grade found on MRI fusion biopsy matched final pathology in 46% of the cases while it was overestimated in 15% of patients and underestimated in 39%. Cancer found on traditional systematic biopsy matched final pathology in 56% of patients while it overestimated grade in 26% and underestimated grade in 17% of patients with GS!7. The highest Gleason score from combined MRI fusion and systematic biopsy only underestimated 11% of patients but overestimated grade in 33% of patients who had GS!7 on their final pathology. In the logistic regression model, having a GS ! 3þ4 detected on MRI fusion biopsy was associated with higher odds (OR: 3.5 95% CI 1.3-9.3, p <0.01) of higher stage cancer (!pT3a) at RP. The association persisted when the model was adjusted for clinical CAPRA score. This study was limited by its retrospective nature.
CONCLUSIONS: Risk of over -staging using MRI fusion biopsy is low compared to systematic biopsy. However, MRI fusion biopsy alone could significantly underestimate those with clinically significant disease. Using MRI fusion biopsy alone to detect high grade cancer may not be adequate in this contemporary cohort. This data may have important implications for guiding treatment decisions.
Source of Funding: none
MP20-10 THE ACCURACY OF MAGNETIC RESONANCE IMAGING (MPMRI) GUIDED TRANSPERINEAL FUSION PROSTATE BIOPSIES (TPFB) TO EVALUATE LESIONS ON PROSTATE MPMRI USING PROSTATECTOMY SPECIMENS AS A VALIDATION TOOL.
INTRODUCTION AND OBJECTIVES: Prostate mpMRI guided biopsies improve detection of Gleason score ¼7cancer (PCa). The objective of the current study is to assess diagnostic reliability in comparison to definitive histological diagnosis. We present a retrospective analysis of our detection accuracy of PCa by mpMRI and TPFB in comparison to histological specimens from Robotic-Assisted Radical Prostatectomy (RARP).
METHODS: 1002 men have had TPFB at Cambridge University Hospitals Trust between March 2012 and April 2016. 93 have subsequently undergone RARP for PCa. mpMRI was performed on all 93 patients and reported according to PIRADSvs2. 79/93 (84.9%) patients had ¼1 mpMRI lesions with Likert score > 2 (Likert 3¼11; Likert 4¼27; Likert 5¼41). TPFB was performed on each patient. 2-4 samples were taken from the target zone identified on mpMRI (TB) and 18-24 samples systematically taken according to Ginsburg protocol (SB). 14/93 had a negative mpMRI but were diagnosed with PCa following SB. Samples were retrospectively compared to RARP histology. Data was examined e242 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 
